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Chapter 6
The ARCHITECT galectin-3 assay:  
comparison with other automated and manual 
assays for the measurement of circulating 
galectin-3 levels in heart failure
Wouter C. Meijers, A. Rogier van der Velde, Rudolf A. de Boer
Expert Rev Mol Diagn. 2014;14:257-266.
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aBsTRaCT
Heart failure (HF) is a common disease and affects millions of patients worldwide. 
Diagnosis, risk assessment, and treatment of HF are difficult and therefore there is a 
need for additional tools to improve clinical performance. Biomarkers may be helpful 
in this respect. Galectin-3 is a relatively new biomarker that has been shown to have 
strong associations with the development of HF. Galectin-3 plays a role in inflammation 
and fibrosis, which are key elements in the pathophysiology of HF. Circulating plasma 
or serum galectin-3 levels have strong associations with severity of HF and may be used 
to prognosticate or risk-stratify HF patients. Currently, there are several commercially 
available assays that can measure circulating galectin-3. This article describes the role 
galectin-3 plays in HF and its prognostic consequences. We will summarize the technical 
specifications of various manual and automated galectin-3 assays, which may help in HF 
management.
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InTRoDUCTIon
Heart failure
Heart failure (HF) is a common cardiac disease and is estimated to affect around 23 mil-
lion people worldwide.1 People at the age of 40 have a lifetime risk of 20% to develop 
HF.2 The prevalence of HF is on the rise due to the aging population and the increased 
life expectancy owing to better treatment options.
HF is a clinical syndrome that occurs when the heart is unable to deliver oxygen at the 
level that is required by the metabolizing tissues and the simultaneous presence of 
structural changes in myocardial tissue or function. Key symptoms that reflect these 
changes include shortness of breath, fatigue, orthopnea, and physical signs such as 
elevated jugular venous pressure, pulmonary crackles, ankle edema and a displaced 
apex beat. The diagnostic value of most of these symptoms and signs is however limited. 
Many signs of HF are the result of fluid retention or congestion and are readily treated 
with diuretic therapy. To classify the stage of disease based upon function, the New York 
Heart Association (NYHA) functional classification can be used, ranging from NYHA class 
I (no symptoms) to class IV (symptoms at rest).3 It has to be noted that symptom severity 
is not linearly related with ventricular dysfunction. Patients with severe symptoms are 
more likely to be hospitalized or to die, but also patients with mild symptoms have a 
clearly increased risk for hospitalization and death.3 Symptoms may change rapidly - 
deterioration in symptoms indicates increased risk of hospitalization and death, and is 
an indication to seek prompt medical attention and treatment. Reduction of symptoms 
and morbidity, lower mortality and hospital admissions are the major goals in the treat-
ment of HF.
HF is the natural end-stage disease of several types of cardiovascular conditions such 
as coronary artery disease (CAD), myocardial infarction (MI), hypertension, myocarditis, 
uncontrolled arrhythmia such as atrial fibrillation and systemic diseases. Clearly, identifi-
cation of the underlying cardiac problem is crucial for therapeutic options as the precise 
pathology determines the specific treatment used. In response to the index event, the 
heart responds to the imposed stress by a process captured by the term “cardiac re-
modeling”.4 This encompasses myocyte and cardiac hypertrophy to withstand the stress, 
remodeling of the interstitial compartment generally referred to as fibrosis, and changes 
like high influx to other resident or migratory cells such as leukocytes and macrophages. 
Several neurohormonal and inflammatory systems are being activated in the heart 
including the renin-angiotensin-aldosterone system (RAAS),5,6 the sympathetic nervous 
system (SNS),7 and several cytokines such as interleukin-1 (IL1), interleukin-6 (IL6) and 
tumor necrosis factor alpha (TNF-α).8 Although initially aimed at providing coping 
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mechanisms to deal with the excess stress put upon the heart, on the long term, activa-
tion of these “compensatory” mechanisms leads to progressive cardiac remodeling and 
HF development. Studies of these systems and their inadequate activation have resulted 
in the development of inhibitors of the RAAS and the SNS, which have become corner-
stones in the treatment of HF.9,10 In recent decades, the use of intra cardiac defibrillators 
(ICDs) and cardiac resynchronization therapy (CRT) has further improved outcome.11,12 
Despite better treatment options, rehospitalization and mortality rates of HF patients 
are still unacceptably high.13
Although HF is generally regarded as a single disorder, we currently recognize subforms 
within the spectrum. Since long, heart failure has been classified according to its origin, 
for instance ischemic versus non-ischemic or dilated versus hypertrophic. Currently, we 
recognize another two main subtypes of HF, namely HF with reduced ejection fraction 
(HFrEF) and HF with preserved ejection fraction (HFpEF). The relative incidence of HFrEF 
and HFpEF has been evaluated in several community-based cohorts studies, including 
the PREVEND study,14 the Framingham Heart Study,15 and the Cardiovascular Health 
Study.16 Beside the simple differences in ejection fraction, more relevant differences can 
be observed between these subforms of HF. HFpEF patients are mostly elderly people 
and commonly have hypertension, atrial fibrillation, and obesity.17,18 Very different from 
HFrEF, at the moment, there is no evidence-based or efficacious pharmacological strat-
egy to treat HFpEF patients.3 In HFrEF, current guidelines do provide evidence-based 
therapies, however, residual risk remains high.3
So, in spite of a number of potential therapies, HF remains a condition with autonomous 
progression and an accordingly high event rate. A potential explanation for this might 
be that therapies may have been used invariably in inappropriate patient groups in 
clinical trials. It has been postulated that different “drivers” may exist in subgroups of HF 
patients and targeting these drivers with specific therapies might propel understanding 
and prognosis of HF. In such an approach of tailored medicine, certain medications may 
be more beneficial in one sub group compared with others.
Biomarkers may not only be beneficial for risk assessment or improving diagnostic per-
formance of HF, but could be of great potential if they could differentiate the patients 
into categories. The research of biomarkers has exploded over the past decade.19-24 The 
natriuretic peptides (NPs), such as (N-terminal-pro) B-type natriuretic peptide (NT-pro 
BNP) or atrial NP (ANP), have been extensively studied and proved to be excellent 
biomarkers for the diagnosis and the prognosis of HF with reasonable ability to guide 
therapy.25-27 However, NPs have some limitations, and HF-related clinical events are still 
all too common. Therefore, the search for additional biomarkers has attracted consider-
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able attention, and several novel biomarkers for HF have been discovered and described. 
The utility of biomarkers in HF has been reviewed in several recent articles.21-23,28 One of 
these biomarkers is galectin-3,29 a lectin (carbohydrate-binding protein) with intrigu-
ing biology and that can reliably be measured in the plasma or serum as a biomarker 
for HF. Table 1 shows the characteristics of galectin-3 when judged in comparison with 
natriuretic peptides.
Galectin-3
Galectin-3 is a β-galactoside-binding member of the lectin family. Galectin-3 is encoded 
by a single gene, LGALS3, located on chromosome 14, locus q21–q22,30 has a carbohy-
drate recognition-binding domain (CRD) and an N-Terminal, is 30 kDa of size and can bind 
specific β-galactosidases.31,32 Upon ligand binding, galectin-3 acts on fibroblast that turn 
into myofibroblast by differentiation, with subsequent collagen production.33-35 It has 
also been associated with cell-cell interaction, for example, in wound healing,36 but also 
in formation of cancer and metastases.37-39 Also extra-cardiac production of galectin-3 
has been reported.40 Furthermore, galectin-3 has a role in the inflammatory response 
and alternative macrophage activation.41 Inflammation is an important factor in cardiac 
remodeling and HF. Besides pro-inflammatory cytokines and cytokine receptors, mol-
ecules that are released by macrophages and monocytes such as galectin-3 correlate 
with disease severity and are predictive for worsening HF.42 If, and to what extent, the 
pro-inflammatory role of galectin-3 plays a role in HF is currently unknown. Galectin-3 
seems to play an important role in both processes.43 Finally, galectin-3 has established 
effects in cardiac remodeling and HF development, as discussed below.
Galectin-3: pre-clinical data on its role in cardiac remodeling
A microarray study using transgenic hypertensive HF-prone rats (Ren-2 rats), showed 
that galectin-3 was the most overexpressed gene in the transition from compensated 
toward decompensated HF.33 Various other glycoproteins like laminin, collagen, synexin 
and integrins in the extracellular matrix that may interact with galectin-3 were com-
monly activated during cardiac remodeling in the Ren-2 rats.21 Further experiments 
showed that continuous infusion of galectin-3 for 4 weeks into the pericardial sac in-
Table 1. The utility of galectin-3 as a biomarker in heart failure compared to natriuretic peptides 
(adapted from van Kimmenade et al.76)
Criteria natriuretic peptides Galectin-3
Sensitive (diagnosis) ++++ -
Prognosis ++++ ++
Therapy guidance ++ ?
Cardiac production Solely Not exclusively
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duced cardiac remodeling, myocardial fibrosis and cardiac dysfunction, with depressed 
left ventricular ejection fraction (LVEF), fractional shortening and increased lung-weight 
to body-weight ratio compared to rats receiving placebo infusion. They also found an 
increase in collagen volume, especially collagen type I.33 The role of galectin-3 in fibrosis 
formation was further intensively studied using mice deficient for the gene-encoding 
galectin-3 (Gal3KO mice). In Gal3KO mice, fibrosis formation was almost completely pre-
vented in a model of liver fibrosis and also in a model of kidney fibrosis.35,44 In a model of 
unilateral uninephrectomy, Gal3KO mice showed reduced collagen deposition and less 
macrophage influx although expression levels of TGF-β and Smad 2/3 phosphorylation 
were comparable. More importantly, we have recently shown that Gal3KO mice sub-
jected to various modes of cardiac stress also were resilient to myocardial fibrogenesis.34 
On the same note, we observed that pharmacological inhibition of galectin-3 reduced 
fibrosis in Ren-2 rats.34 From this, it appears that galectin-3 is an important factor in the 
pathophysiology of fibrotic disease, including heart disease and HF. Further research 
is necessary to study if direct targeting or inhibition of galectin-3 is feasible and could 
play a role in HF treatment. Aldosterone has also been linked to galectin-3 and forma-
tion of fibrosis. In a mouse model with elevated angiotensin II and aldosterone, the 
mineralocorticoid receptor antagonist eplerenone lowered galectin-3 expression in the 
myocardium.45 In other models of HF associated with elevated angiotensin II, it has also 
been observed that galectin-3 levels are elevated.46-48 The interaction between aldoste-
rone antagonists and galectin-3 is currently under investigation.
Galectin-3 - clinical data
General population
The first observation study on the predictive role of galectin-3 in the general popula-
tion described 7,968 subjects (mean age 50 years, 50% males), which were enrolled in 
the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. Galectin-3 
predicted all-cause mortality and was associated with age and general risk factors of 
cardiovascular disease. In the Framingham Offspring Cohort (3353 participants, mean 
age 59 years, 47% males), higher concentrations of galectin-3 were associated with 
increased risk for incident HF and mortality. In both studies, the circulating levels of 
galectin-3 were between 10-14 ng/mL.49,50
Acute heart failure
The first report on the value of galectin-3 as a biomarker for HF dates back to 2006. 
In predicting the 60-days mortality, galectin-3 showed better prognostic value than 
NT-proBNP51 in the ProBNP Investigation of Dyspnea in the Emergency Department 
(PRIDE) study. In another cohort of acute HF, the Coordinating study evaluating Out-
comes of Advising and Counseling in Heart failure (COACH) study, baseline galectin-3 
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levels (sampling at discharge after event), had strong prognostic value, also when cor-
rected for age, sex, BNP, renal function and DM. Combination of galectin-3 and BNP may 
be useful in patients with either one of these biomarkers at a low level. This may be 
explained by the notion that both biomarkers mirror different aspects of the disease: 
fibrosis (galectin-3) versus wall stress (NT-proBNP). Galectin-3 seems to be a more stable 
marker overtime.52 Another interesting observation in this analysis was that galectin-3 
appeared to have particularly strong predictive value in HFpEF patients compared to 
HFrEF patients.53 This observation is supported by a long-term follow-up of the PRIDE 
cohort, where galectin-3 significantly correlated with echocardiographic parameters of 
diastolic function.54 This observation connects the theory of galectin-3’s involvement in 
collagen deposition, fibrosis formation and progressive stiffening of the cardiac muscle, 
which affects the diastolic function of the heart.55
Chronic heart failure
Currently, several articles have been published about the value of galectin-3 in chronic 
HF (CHF) patients. The first study was the Deventer-Alkmaar HF (DEAL-HF) study,56 a study 
of CHF patients with NYHA classes III and IV who were followed for approximately 6.5 
years. Plasma galectin-3 was significantly associated with mortality. These observations 
were confirmed in a smaller study with CHF patients of NYHA classes II-IV. Galectin-3 
was a significant predictor of mortality, also after correction for NT-proBNP. Galectin-3 
levels were correlated with NYHA class, but not to the etiology of HF.57 Plasma galectin-3 
and echocardiographic measurements were assessed in a CHF patient cohort. Higher 
galectin-3 was associated with more advanced age, poor renal function and predicted 
all-cause mortality. In multivariate analysis, galectin-3 remained an independent predic-
tor of all-cause mortality after adjusting for age, estimated glomerular filtration rate, 
LVEF, and mitral early diastolic myocardial relaxation velocity at septal mitral annulus. No 
relation between galectin-3 and echocardiographic measurements were found.58
Several other post-hoc analyses from large CHF studies, including the Controlled Rosuv-
astatin Multinational Study in Heart Failure (CORONA), the HF - A Controlled Trial Investi-
gating Outcomes in Exercise TraiNing (HF-ACTION), and the Valsartan Heart Failure Trial 
(Val-HeFT), and several more studies, all have confirmed the potential role of galectin-3 
for the purpose of prognostication and risk stratification.59-61 Most studies reported an 
independent value of galectin-3 when added to currently used tools for risk stratification, 
however, important confounders of galectin-3 that were reported were age, sex, renal 
function, and NT-proBNP and this requires further study. Whether increased galectin-3 
levels are primarily due to cardiac production, or due to extra cardiac production as well, 
is not completely understood. Patients who had high levels of galectin-3 before total 
artificial heart (TAH) implantation showed no significant changes in galectin-3 levels 30 
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days after the TAH implantation,62 an observation suggesting extracardiac production of 
galectin-3 in patients with end-stage HF. However, higher galectin-3 levels still predicted 
adverse outcome.62
When comparing all currently published studies (general population, acute HF, chronic 
HF) with galectin-3 plasma levels and mortality, we observed a clear association be-
tween the galectin-3 levels, and annual mortality, displayed in Figure 1.
Furthermore, Figure 2 displays median galectin-3 levels (with interquartile ranges) of 
different cohorts, which comprises the general population, (acute and chronic) HF, and 
hemodialysis patients.63 Between cohorts comprising seemingly identical patients, ga-
lectin-3 levels varied substantially. This could imply that in these cohorts some patients 
are more “galectin-3 driven” than others. It is interesting to speculate that patients with 
galectin-3 driven disease may benefit from specific treatment options.
Diagnostic tests for galectin-3 measurements
General considerations
Blood should be collected using standard venous blood collection techniques. Serum or 
EDTA plasma may be used in all tests described. Samples with visible haemolysis should 
not be used as falsely elevated galectin-3 levels will occur. If necessary, then serum or 
plasma may be stored for future analysis. Galectin-3 in human EDTA-plasma and serum 
has been shown to be stable for nine freeze-thaw cycles after storage at -20°C or -70°C.
BG Medicine
The Galectin-3 ELISA kit by BG Medicine (BGM) is a microtiter plate-based ELISA validated 
for the quantitative determination of galectin-3 levels in serum and EDTA plasma, with a 
required sample volume of 30 μL. It uses two monoclonal antibodies against galectin-3. 
The capture antibody is a rat monoclonal anti-mouse galactin-3 antibody and is pre-


























CARE-HF figure 1. Galectin-3 levels in cohorts and the 
annual all-cause mortality
The annual all-cause mortality (%) between the 
different studies based upon the median plasma 
galectin-3 levels. A regression line is plotted that 
fits the best overall relationship. Green dot: Gen-
eral population cohort; Orange dot: Heart Failure 
cohort
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coated onto the surface of the wells in a microtiter plate. After binding of this antibody, 
galectin-3 is attached to the well while rinsing of the sample removes any unbound 
compounds and residual sample.
A second provided antibody, which is added later on, is the mouse monoclonal anti-
human galectin-3 antibody. It is labeled with horseradish peroxidase (HRP) and acts as a 
tracer, used to visualize the galectin-3 molecules that have settled to the well’s surface. 
During incubation of the second antibody, an antibody-antigen-antibody complex is 
formed. Before the results can be read-out, a tetramethylbenzidine (TMB) substrate 
is added, inducing a blue color in the presence of HRP. This process is stopped when 
sulfuric acid is added; the intensity of the color can then be read at an absorbance of 
450 nm. The absorbance is proportional to the galectin-3 levels in the specimens. The 
test results of the specimens are read from the standard curve; the concentrations are 
expressed in ng/mL.   The specificity, coefficients of variation (CVs), and normal values 
have been published  elsewhere.64,65
figure 2. Galectin-3 plasma levels and interquartile ranges in different cohorts
The variety between the galectin-3 levels in different cohorts. General population: PREVEND50 – Prevention 
of REnal and Vascular ENd-stage Disease; Framingham49; HF-ACTION60 - Heart Failure: A Controlled Trial In-
vestigating Outcomes of Exercise Training; PRIDE54 - the ProBNP Investigation of Dyspnea in the Emergency 
Department; Val-HeFT61 - The Valsartan Heart Failure Trial; VitD-CHF6 – Vitamin D Chronic Heart Failure; 
DEAL56 - Deventer–Alkmaar Heart Failure Study; CORONA59 - Controlled Rosuvastatin Multinational Trial in 
Heart Failure; COACH53 - The Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart 
Failure; CARE-HF74 - Cardiac Resynchronization in Heart Failure; End Stage Kidney Disease patients: 4D63 - 
Die Deutsche Diabetes Dialyse Studie (English: The German Diabetes Dialysis Study). Green dot: General 




One advantage of the sample collection of the ARCHITECT is that only a small amount 
of EDTA-plasma or human serum is needed in comparison with the other automated 
devices, namely only 25µL (excluding the dead volume).
Assay methodology
The ARCHITECT galectin-3 assay is a chemiluminescent microparticle immunoassay 
(CMIA) for the quantitative determination of galectin-3 in human serum and EDTA 
plasma samples. The ARCHITECT  iSystem is used for execution of the assay, and  two 
Abbott ARCHITECT systems may be used, the  i1000SR and the  i2000SR. The ARCHITECT 
i1000SR analyzer is one of the immunoassay members of the ARCHITECT family, and 
this system is designed for lower – mid volume laboratories and for integration with 
the c4000 chemistry analyzer. The ARCHITECT i2000SR provides immunoassay testing 
with increased sample and reagent capacity. Each i2000 module will perform up to 200 
tests per hour with up to 25 reagents onboard. ARCHITECT i2000SR can be integrated 
with the ARCHITECT c8000 or ARCHITECT c16000 to consolidate clinical chemistry and 
immunoassay on one platform. The dimensions of the machine in inches are, height 
x width x depth, respectively 48 × 61 × 49. The assay can be performed in 2 testing 
modes, STAT with short turnaround time of 18 minutes and ROUTINE with turnaround 
time of 28 minutes. In an automated process, the ARCHITECT uses chemiluminescent 
immunoassay (Chemiflex®) technology that incorporates acridinium with a derivative 
tracer. After sample incubation and rinsing of the sample, a decomposition reaction 
occurs with the acridinium. The read-out is measured via relative light units after the 
emitted chemiluminescence signal is amplified. The larger the concentration of the ga-
lectin-3 in the sample is, the higher the emission of photons. In the ARCHITECT iSystem, 
25 different reagent packs can be loaded and stored in an incorporated refrigerated 
unit. Test results can either be transmitted via a bi-directional interface to a central data 
repository or stored in memory of the analyzer computer. An advantage of this analyzer 
is the robotic sample handler, which allows both reagents to load while the analyzer is 
in the middle of the testing process and ensures preemptive priority for STAT sampling 
over routine samples. The ARCHITECT uses the same monoclonal antibody as well as the 
same capture antibody and conjugate used in the BG Medicine ELISA kit.66,67
A family of ARCHITECT assays
The galectin-3 ARCHITECT assay is part of the ARCHITECT assays, a family with more 
FDA-cleared assays for measuring biomarkers linked to cardiac disease. For example 
BNP, CK-MB, Myoglobin, and Troponin-I. All these measurements can be assessed in 
the i1000SR and the i2000SR. With this family of assays, detection of different cardiac 
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parameters can be measured using the same methodology and equipment, making it 
practical, convenient, as well as rapid and reliable.
Research & Development (R&D)
The R&D ELISA uses the exact same technique as used in the BGM ELISA, namely a 
quantitative sandwich enzyme immunoassay with a specific monoclonal antibody 
for galectin-3. Samples are pipetted into precoated wells and any galectin-3 present 
is bound by the immobilized antibody. After washing, an enzyme-linked polyclonal 
antibody specific for galectin-3 is added to the wells. Following another washing step, a 
substrate solution is added to the wells and color intensity develops in proportion to the 
amount of galectin-3 present. The requested sample volume is 50 μL. No information is 
available about the antibodies used. Since the standard curve is substantially different 
from the BGM ELISA, we assume different solutions are used, but no details are provided 
in the PDF forms that are publicly available.68
Biomérieux: VIDas
VIDAS is an automated quantitative test to determine the human galectin-3 in serum or 
plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique. The VIDAS uses 
an immunoassay sandwich, which is combined with fluorescent detection. The VIDAS 
immunoassay testing system uses a solid phase receptacle (SPR) and a ready-to-use 
reagent strip system. The SPR is coated with antigens or antibodies. It acts as a pipetting 
and a solid phase device. At each stage of the reaction, it aspirates the reagents in and 
out. This prevents any inter-reagent or inter-sample contamination during immuno-
assay tests. In addition, the absence of tubing, syringes and needles reduces system 
maintenance. Reagents for the assay are ready-to-use and pre-dispensed in a strip. The 
dimensions of the machine in inches are, height x width x depth, respectively 23 x 39 x 
27.
The sample, with a requested volume of 200 μL, will be drawn in and out of the pipet tip 
into a bath of anti-galectin-3 antibody labeled with alkaline phosphatase. This will allow 
the galectin-3 to bind the immunoglobulins fixed to the interior wall of the SPR and to 
the conjugate in order to form a sandwich. The samples will be rinsed to remove any 
unbound particles.
A detection step is followed by the final step, in which the substrate (4-methyl-
umbelliferyl phosphate) is cycled in and out of the SPR. The ensemble of the conjugate 
enzymes catalyzes the hydrolysis of this substrate into a fluorescent product (4-methyl-
umbelliferone), which can be measured at 450 nm. The emission intensity is representa-
tive for the concentration of galectin-3 present in the sample. The instrument calculates 
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the results, taking the calibration curve as stored in memory into account. Concentra-
tions are expressed in ng/mL. The VIDAS Galectin-3 assay is standardized against the BG 
Medicine Galectin-3 test.69
alere
The assay is performed in 384-well microtiter plate using a Tecan for all liquid handling 
steps. The method is sandwich assay based and uses a biotinylated antigen. The ELISA-
plate needs to be washed three times with borate buffered saline containing 0.02% 
Tween 20 (BBS-Tween). Besides regular samples, test samples (10 µL/well) and a cali-
bration curve are added to the 384-well plate. The calibration curve is prepared gravi-
metrically in plasma from healthy donors. In situation where the sample must be diluted 
to fit within the calibration curve, the calibrators are prepared in a CD8 assay buffer (10 
mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1 mmol/L MgCl2, 0.1 mmol/L ZnCl2, 10 mL/L 
polyvinyl alcohol (MW 9000–10 000), 10 g/L bovine serum albumin, and 1 g/L NaN3), 
which is also used for sample dilution. The plates are read by a Tecan Infinite. Calibration 
curves will be tested at eight different points tested across the assay plate. The calibra-
tion curve is calculated using a five-parameter logistic fit and sample concentration can 
be determined. The inter- and intra-observer CV is 5% and 12%, respectively, and the 
lower and higher cut-off levels are 0.5 ng/mL and 86.2 ng/mL. For liquid handling of the 
samples and measuring the concentrations, machinery from Tecan is used.70
Table 2 displays all the characteristics of the different galectin-3 tests currently on the 
market. One of the first - and still the most commonly used - diagnostic methods for 
galectins-3 measurements is the BGM ELISA kit. Although this test is routinely used in 
clinical trials, it has one important limitation and that is the duration of the ELISA. It takes 
up to 3.5 hours to perform one test. Collaboration of BGM with Abbott led to the first 
automated platform for galectin-3 measurements, the ARCHITECT.
Which assay to use?
There are differences between the assays, as we describe, and this may steer the choice 
of an appropriate assay. For daily routine, the ARCHITECT assay is an attractive option, 
with short turnaround times, the possibility to have galectin-3 tested in combination 
with several other standard blood tests and the possibility to offer galectin-3 testing 
to several doctors, departments and even hospitals. It does however require a certain 
volume to upkeep the system, its calibration, and to avoid expiration of the (expensive) 
chemicals. In lower volumes centers, the VIDAS assay is more suitable, as it allows rapid 
sampling (e.g. bed side testing) as with ARCHITECT, however, costs will be higher per 
sample, and the tests cannot be run in parallel to other standard blood tests, such as 
hematology, chemistry, or NT-proBNP. Finally, in large cohorts, for instance study co-
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horts, where manual labour is less of a limitation the BGM assay is still a good and cheap 
alternative.
antibodies
Focusing on the three assays mentioned above, it has been reported that the ARCHI-
TECT and the BGM assay both use the same antibodies. Specifically, the capture anti-
body pre-coated on the plate is a M3/38 anti-Galectin-3 rat monoclonal antibody and 
galectin-3 present in the sample will bind this M3/38 antibody. After a wash step, 87/
B5 anti-Galectin-3 mouse monoclonal acridinium-labelled conjugate is added forming 
an antibody-antigen sandwich. Due to proprietary reasons Biomeriéux cannot report 
the details of the VIDAS antibodies. However, the VIDAS assay against is standardized to 
the BGM assay, suggesting that antibodies with identical affinity are being used in both 
assays. A comparison study with the BGM assay (n = 130) shows an excellent correlation 
and agreement between both methods, with minimal bias at the cutpoints of 17.8 and 
25.9 ng/mL.


































































































BGM 30 3.5h 3.2 5.6 0.86 1.13 1.32 1.4-94.8 ** # 19.0 22.1 26.2
aRCHITeCT – stat 25* 18min 3.4 4.1 0.8 1.0 4.0 4.0-114.0 ** # 22.4 25.7 27.5
aRCHITeCT - Routine 25* 28min 4.1 4.9 0.8 1.0 4.0 4.0-114.0 ** # 22.4 25.7 27.5
VIDas 200 20min 1.3 5.5 2.2 2.4 3.3 3.3-100 ** # - - -
R&D 50 4.5h 3.9 5.9 - 0.02 - 0.313 - 10 ** # 9.1 9.9 10.6
aleRe 10 - 12 5 - - - 0.5-86.2 ** # - - -
* Plus 50µL dead volume
**No interference with conjugated bilirubin, unconjugated bilirubin, lipidemia, triglycerides, bovine serum 
albumin, cholesterol, creatinine, hemoglobin, Galectin 1, 2, 4, 7, 8, 9, 10, 14, MAC-2BP and common used 
cardiovascular medication; Interference with hemolyzed samples, human anti-mouse antibody, rheuma-
toid factor and verapamil.
# No cross-reactivity with Collagen I and III and 9 other Galectins
§ Percentiles based on general population
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expert commentary
The use of galectin-3 as a biomarker has received increasing interest in the last decade, 
overall and especially in HF (Figure 3). Galectin-3 has received a class IIB recommenda-
tion in the most recent ACC/AHA guidelines for HF, as an aid in prognostication and 
risk stratification of patients with acute and chronic heart failure.71 For proper use and 
interpretation of galectin-3, the use of a reliable and high-throughput assay clearly is a 
strong prerequisite.
Several publications reporting on galectin-3 are difficult to interpret as they used as-
says, which are difficult to compare to the ones we describe in this article.72,73 The large 
majority of published data report on data derived by the BGM ELISA kit, which is the only 
FDA-approved assay for measuring galectin-3. Newer automated (ARCHITECT) or semi-
automated (VIDAS) assays (probably) employ the same antibodies as the BGM assay, 
and are calibrated to it, so should be regarded as high-throughput versions of this assay.
five-year view
The automated galectin-3 assays, such as the ARCHITECT galectin-3 assay, open up a 
new era of galectin-3 testing. This will allow for quick, easy and reliable measurement 
of plasma and/or serum levels of galectin-3. The registered use of galectin-3 is confined 
to prognostication and risk stratification of HF. Although this indication is of interest, we 
foresee several other interesting potential roles for galectin-3. First, a high galectin-3 
may not only be a signal, but rather be a “phenotype” that should prompt doctors to 
order additional tests (renal function, albuminuria, steatosis), and possibly to “act on” 
on this. Further, trials are being launched that will address the question if galectin-3 
might be a tool to guide treatment. So, we speculate that in the future galectin-3 might 
be measured to differentiate subtypes of HF or other cardiovascular or renal disease. 
























































figure 3. Publications of Galectin-3 over the past years
A, Galectin-3 publications in general; B, Galectin-3 publications in heart failure
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galectin-3 treatments will become available, then follow-up measurements of plasma 
galectin-3 will be needed in monitoring disease development.
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